OraSure posts record Q3 revenue of $116.5M, up 116% YoY; InteliSwab drives growth

ORASURE TECHNOLOGIES INC

2022-Q3 EPS reported -$0.46 revenue$264,401,000

GAAP net income $5.3M ($0.07 diluted EPS) vs. loss of $15.0M a year ago; non-GAAP EPS $0.13.
InteliSwab COVID-19 test revenue $79.6M, up 85% sequentially; core diagnostics revenue +14% YoY.
Q3 operating cash flow $16.3M positive vs. ($19.1M) in 2021; cash balance $101.6M.
Q4 revenue guidance $95-100M (49-57% YoY growth); expects continued positive cash flow.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ORASURE TECHNOLOGIES INC reported the three months ended September 30, 2022 results: revenue $116.5 million, net income $5,273, EPS 0.07.

Period: the three months ended September 30, 2022
Revenue: $116.5 million
Net income: $5,273
EPS: 0.07
Result: reported results

Exact text from the filing

Communications 484-425-0588 sgleason@orasure.com Media Contact: Amy Koch Sr. Mgr. Corporate Communications 484-523-1815 media@orasure.com OraSure Reports 3Q22 Record Revenue of $116.5 Million Growing 116% Year-Over-Year InteliSwab® revenue of $79.6 million in Q3, up 85% sequentially; Company continues to expand test production capacity Company wins new contracts for

View on SEC.gov

Browse all earnings releases →

ORASURE TECHNOLOGIES INC filing history →

Source: SEC EDGAR

accession 0000950170-22-023216

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.